Cargando…
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial
AIMS: Cardiopoietic cells, produced through cardiogenic conditioning of patients’ mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort...
Ejemplares similares
-
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design
por: Bartunek, Jozef, et al.
Publicado: (2015) -
Cardiopoietic stem cell therapy in ischaemic heart failure: long‐term clinical outcomes
por: Bartunek, Jozef, et al.
Publicado: (2020) -
Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure
por: Bartunek, Jozef, et al.
Publicado: (2023) -
Secretome signature of cardiopoietic cells echoed in rescued infarcted heart proteome
por: Arrell, D. Kent, et al.
Publicado: (2021) -
Cardiomyocytes Derived from Human (Cardiopoietic)Amniotic Fluids
por: Di Baldassarre, Angela, et al.
Publicado: (2018)